Novartis Beats Earnings & Sales in Q2
July 19, 2016 at 06:53 AM EDT
The strong performance of growth products (Gilenya, Cosentyx among others) offset the impact of generic competition for key drugs (Gleevec).The generic arm, Sandoz also performed well. However, sales from Alcon continue to disappoint.
